Compare · MRK vs ROIV
MRK vs ROIV
Side-by-side comparison of Merck & Company Inc. (MRK) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $358.21B, about 14.6x ROIV ($24.59B).
- MRK has been more active in the news (16 items in the past 4 weeks vs 12 for ROIV).
- MRK has more recent analyst coverage (25 ratings vs 20 for ROIV).
- Company
- Merck & Company Inc.
- Roivant Sciences Ltd.
- Price
- -
- -
- Market cap
- $358.21B
- $24.59B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 16
- 12
- Recent ratings
- 25
- 20
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest MRK
- SEC Form 8-K filed by Merck & Company Inc.
- Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
- Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
- Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
- CAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program
Latest ROIV
- Roivant Sciences downgraded by Wolfe Research
- Amendment: SEC Form SCHEDULE 13D/A filed by Roivant Sciences Ltd.
- SEC Form 4 filed by Roivant Sciences Ltd.
- SEC Form 4 filed by Roivant Sciences Ltd.
- CEO Gline Matthew covered exercise/tax liability with 76,171 shares, decreasing direct ownership by 0.46% to 16,583,774 units (SEC Form 4) to satisfy withholding tax
- President and Vant Chair Torti Frank increased direct ownership by 0.30% to 13,495,893 units (SEC Form 4) to satisfy withholding obligation
- President & CIO Sukhatme Mayukh covered exercise/tax liability with 46,879 shares, decreasing direct ownership by 0.25% to 18,583,860 units (SEC Form 4) to satisfy withholding tax
- President & Immunovant CEO Venker Eric sold $7,324,000 worth of shares (200,000 units at $36.62) as part of a pre-agreed trading plan and exercised 200,000 shares at a strike of $3.85 (SEC Form 4)
- Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
- Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus